{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:11:22Z","timestamp":1789042282264,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":99,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009526","name":"Amrita Vishwa Vidyapeetham","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009526","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53367-w","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:23:51Z","timestamp":1780439031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of 1-(substituted benzofuran-2-yl)-3-(halogen-substituted phenyl)prop-2-en-1-ones as potent, reversible, and selective MAO-B inhibitors for Parkinson\u2019s Disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Ali","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiseong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Payyaula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu Vasanthi","family":"Radhakrishanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachithra Thazhathuveedu","family":"Sudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Della Grace Thomas","family":"Parambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasim Sakran","family":"Abass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseer","family":"Maliyakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijo","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"53367_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1021\/tx010073b","volume":"14","author":"AS Kalgutkar","year":"2001","unstructured":"Kalgutkar, A. S., Dalvie, D. K., Castagnoli, N. & Taylor, T. J. Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors. Chem. Res. Toxicol. 14, 1139\u20131162. https:\/\/doi.org\/10.1021\/tx010073b (2001).","journal-title":"Chem. Res. Toxicol."},{"key":"53367_CR2","doi-asserted-by":"publisher","first-page":"9211","DOI":"10.1016\/S0021-9258(19)52530-3","volume":"256","author":"RH Huang","year":"1981","unstructured":"Huang, R. H. & Faulkner, R. The role of phospholipid in the multiple functional forms of brain monoamine oxidase. J. Biol. Chem. 256, 9211\u20139215 (1981).","journal-title":"J. Biol. Chem."},{"key":"53367_CR3","doi-asserted-by":"publisher","unstructured":"Maiti, P., Manna, J. & Dunbar, G. L. Current understanding of the molecular mechanisms in Parkinson\u2019s disease: Targets for potential treatments, TranslNeurodegener 6 28. (2017). https:\/\/doi.org\/10.1186\/s40035-017-0099-z","DOI":"10.1186\/s40035-017-0099-z"},{"key":"53367_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/978-3-211-92660-4_16","volume-title":"Birth, life and death of dopaminergic neurons in the substantia nigra","author":"N Eriksen","year":"2009","unstructured":"Eriksen, N., Stark, A. K. & Pakkenberg, B. Age and Parkinson\u2019s disease-related neuronal death in the substantia nigrapars compacta, in: Birth, life and death of dopaminergic neurons in the substantia nigra, Springer Vienna, Vienna, : 203\u2013213. https:\/\/doi.org\/10.1007\/978-3-211-92660-4_16. (2009)."},{"key":"53367_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1021\/acschemneuro.8b00313","volume":"10","author":"J Zheng","year":"2019","unstructured":"Zheng, J., Zhang, X. & Zhen, X. Development of adenosine A2A receptor antagonists for the treatment of Parkinson\u2019s disease: A recent update and challenge. ACS Chem. Neurosci. 10, 783\u2013791. https:\/\/doi.org\/10.1021\/acschemneuro.8b00313 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"53367_CR6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet 386, 896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3 (2015).","journal-title":"Lancet"},{"key":"53367_CR7","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.biopha.2017.11.057","volume":"96","author":"G Gao","year":"2017","unstructured":"Gao, G. et al. Morphological analysis of mitochondria for evaluating the toxicity of \u03b1-synuclein in transgenic mice and isolated preparations by atomic force microscopy. Biomed. Pharmacother. 96, 1380\u20131388. https:\/\/doi.org\/10.1016\/j.biopha.2017.11.057 (2017).","journal-title":"Biomed. Pharmacother"},{"key":"53367_CR8","doi-asserted-by":"publisher","first-page":"40699","DOI":"10.1038\/srep40699","volume":"7","author":"N Plotegher","year":"2017","unstructured":"Plotegher, N. et al. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci. Rep. 7, 40699. https:\/\/doi.org\/10.1038\/srep40699 (2017).","journal-title":"Sci. Rep."},{"key":"53367_CR9","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00702-018-1881-5","volume":"125","author":"KF Tipton","year":"2018","unstructured":"Tipton, K. F. 90 years of monoamine oxidase: some progress and some confusion. J. Neural Transm. 125, 1519\u20131551. https:\/\/doi.org\/10.1007\/s00702-018-1881-5 (2018).","journal-title":"J. Neural Transm"},{"key":"53367_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/med.21561","volume":"39","author":"RKP Tripathi","year":"2019","unstructured":"Tripathi, R. K. P. & Ayyannan, S. R. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update. Med. Res. Rev. 39, 1603\u20131706. https:\/\/doi.org\/10.1002\/med.21561 (2019).","journal-title":"Med. Res. Rev."},{"key":"53367_CR11","doi-asserted-by":"publisher","first-page":"112787","DOI":"10.1016\/j.ejmech.2020.112787","volume":"206","author":"S Manzoor","year":"2020","unstructured":"Manzoor, S. & Hoda, N. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer\u2019s disease agents: A review. Eur. J. Med. Chem. 206, 112787. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112787 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"53367_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1080\/17460441.2019.1637415","volume":"14","author":"P Guglielmi","year":"2019","unstructured":"Guglielmi, P., Carradori, S., Ammazzalorso, A. & Secci, D. Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement? Expert Opin. Drug Discov. 14, 995\u20131035. https:\/\/doi.org\/10.1080\/17460441.2019.1637415 (2019).","journal-title":"Expert Opin. Drug Discov"},{"key":"53367_CR13","doi-asserted-by":"publisher","unstructured":"Mathew, B. et al. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer\u2019s and Parkinson\u2019s diseases. Arch. Pharm. (Weinheim). 352. https:\/\/doi.org\/10.1002\/ardp.201900177 (2019).","DOI":"10.1002\/ardp.201900177"},{"key":"53367_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejphar.2017.10.023","volume":"818","author":"HH Chan","year":"2018","unstructured":"Chan, H. H., Tse, M. K., Kumar, S. & Zhuo, L. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties. Eur. J. Pharmacol. 818, 254\u2013262. https:\/\/doi.org\/10.1016\/j.ejphar.2017.10.023 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"53367_CR15","doi-asserted-by":"publisher","first-page":"8184","DOI":"10.1021\/acsomega.2c00397","volume":"7","author":"B Mathew","year":"2022","unstructured":"Mathew, B. et al. Conjugated dienones from differently substituted cinnamaldehyde as highly potent monoamine oxidase-B inhibitors: Synthesis, biochemistry, and computational chemistry. ACS Omega. 7, 8184\u20138197. https:\/\/doi.org\/10.1021\/acsomega.2c00397 (2022).","journal-title":"ACS Omega"},{"key":"53367_CR16","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1021\/jm501690r","volume":"58","author":"S Carradori","year":"2015","unstructured":"Carradori, S. & Silvestri, R. New frontiers in selective human MAO-B inhibitors. J. Med. Chem. 58, 6717\u20136732. https:\/\/doi.org\/10.1021\/jm501690r (2015).","journal-title":"J. Med. Chem."},{"key":"53367_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1586\/14737175.2016.1150783","volume":"16","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret, S. & Rascol, O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson\u2019s disease. Expert Rev. Neurother. 16, 245\u2013258. https:\/\/doi.org\/10.1586\/14737175.2016.1150783 (2016).","journal-title":"Expert Rev. Neurother."},{"key":"53367_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1517\/13543784.2014.897694","volume":"23","author":"L D\u00e9zsi","year":"2014","unstructured":"D\u00e9zsi, L. & V\u00e9csei, L. Safinamide for the treatment of Parkinson\u2019s disease. Expert OpinInvestig Drugs. 23, 729\u2013742. https:\/\/doi.org\/10.1517\/13543784.2014.897694 (2014).","journal-title":"Expert OpinInvestig Drugs"},{"key":"53367_CR19","doi-asserted-by":"publisher","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","volume":"117","author":"C Zhuang","year":"2017","unstructured":"Zhuang, C. et al. Chalcone: A privileged structure in medicinal chemistry. Chem. Rev. 117, 7762\u20137810. https:\/\/doi.org\/10.1021\/acs.chemrev.7b00020 (2017).","journal-title":"Chem. Rev."},{"key":"53367_CR20","doi-asserted-by":"publisher","first-page":"112650","DOI":"10.1016\/j.ejmech.2020.112650","volume":"205","author":"P Guglielmi","year":"2020","unstructured":"Guglielmi, P., Mathew, B., Secci, D. & Carradori, S. Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors. Eur. J. Med. Chem. 205, 112650. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112650 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"53367_CR21","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1016\/j.bmcl.2015.09.049","volume":"25","author":"C Minders","year":"2015","unstructured":"Minders, C., Petzer, J. P., Petzer, A. & Lourens, A. C. U. Monoamine oxidase inhibitory activities of heterocyclic chalcones. Bioorg. Med. Chem. Lett. 25, 5270\u20135276. https:\/\/doi.org\/10.1016\/j.bmcl.2015.09.049 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"53367_CR22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1021\/acsmedchemlett.1c00238","volume":"12","author":"LG Iacovino","year":"2021","unstructured":"Iacovino, L. G. et al. Promisingnon-cytotoxic monosubstituted chalcones to target monoamine oxidase-B. ACS Med. Chem. Lett. 12, 1151\u20131158. https:\/\/doi.org\/10.1021\/acsmedchemlett.1c00238 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"53367_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejmech.2016.02.038","volume":"114","author":"A Hammuda","year":"2016","unstructured":"Hammuda, A. et al. Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors. Eur. J. Med. Chem. 114, 162\u2013169. https:\/\/doi.org\/10.1016\/j.ejmech.2016.02.038 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"53367_CR24","doi-asserted-by":"publisher","first-page":"28182","DOI":"10.1021\/acsomega.1c04252","volume":"6","author":"NA Rehuman","year":"2021","unstructured":"Rehuman, N. A. et al. Halogenated coumarin\u2013chalcones as multifunctional monoamine oxidase-B and butyrylcholinesteraseinhibitors. ACS Omega. 6, 28182\u201328193. https:\/\/doi.org\/10.1021\/acsomega.1c04252 (2021).","journal-title":"ACS Omega"},{"key":"53367_CR25","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2174\/138955712802762301","volume":"12","author":"A Helguera","year":"2012","unstructured":"Helguera, A., Perez-Machado, G., Cordeiro, M. D. S. & Borges, F. Discovery of MAO-B inhibitors - present status and future directions Part I: Oxygen heterocycles and analogs. MiniRev Med. Chem. 12, 907\u2013919. https:\/\/doi.org\/10.2174\/138955712802762301 (2012).","journal-title":"MiniRev Med. Chem."},{"key":"53367_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/0929867327666200121165931","volume":"28","author":"B Mathew","year":"2020","unstructured":"Mathew, B., Carradori, S., Guglielmi, P., Uddin, M. S. & Kim, H. New aspects of monoamine oxidase B inhibitors: The key role of halogens to open the golden door. Curr. Med. Chem. 28, 266\u2013283. https:\/\/doi.org\/10.2174\/0929867327666200121165931 (2020).","journal-title":"Curr. Med. Chem."},{"key":"53367_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bioorg.2019.03.042","volume":"87","author":"K Takao","year":"2019","unstructured":"Takao, K., U, S., Kamauchi, H. & Sugita, Y. Design, synthesis and evaluation of 2-(indolylmethylidene)-2,3-dihydro-1-benzofuran-3-one and 2-(indolyl)-4H-chromen-4-one derivatives as novel monoamine oxidases inhibitors. Bioorg. Chem. 87, 594\u2013600. https:\/\/doi.org\/10.1016\/j.bioorg.2019.03.042 (2019).","journal-title":"Bioorg. Chem."},{"key":"53367_CR28","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/13543776.2019.1673727","volume":"29","author":"KM Dawood","year":"2019","unstructured":"Dawood, K. M. An update on benzofuran inhibitors: a patent review. Expert OpinTher Pat. 29, 841\u2013870. https:\/\/doi.org\/10.1080\/13543776.2019.1673727 (2019).","journal-title":"Expert OpinTher Pat."},{"key":"53367_CR29","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3390\/molecules25102356","volume":"25","author":"JM Oh","year":"2020","unstructured":"Oh, J. M. et al. Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors. Molecules 25, 2356. https:\/\/doi.org\/10.3390\/molecules25102356 (2020).","journal-title":"Molecules"},{"key":"53367_CR30","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ijbiomac.2022.07.178","volume":"217","author":"JM Oh","year":"2022","unstructured":"Oh, J. M. et al. Synthesis of 4-substituted benzyl-2-triazole-linked-tryptamine-paeonol derivatives and evaluation of their selective inhibitions against butyrylcholinesterase and monoamine oxidase-B. Int. J. Biol. Macromol. 217, 910\u2013921. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.07.178 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"53367_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bioorg.2018.10.051","volume":"83","author":"SC Baek","year":"2019","unstructured":"Baek, S. C. et al. Rhamnocitrin isolated from Prunus padus var. seoulensis: A potent and selective reversible inhibitor of human monoamine oxidase A. Bioorg. Chem. 83, 317\u2013325. https:\/\/doi.org\/10.1016\/j.bioorg.2018.10.051 (2019).","journal-title":"Bioorg. Chem."},{"key":"53367_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bmcl.2018.01.049","volume":"28","author":"SC Baek","year":"2018","unstructured":"Baek, S. C. et al. Selective inhibition of monoamine oxidase A by hispidol. Bioorg. Med. Chem. Lett. 28, 584\u2013588. https:\/\/doi.org\/10.1016\/j.bmcl.2018.01.049 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"53367_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijbiomac.2020.02.144","volume":"151","author":"JM Oh","year":"2020","unstructured":"Oh, J. M. et al. Calycosin and 8-O-methylretusin isolated from Maackiaamurensis as potent and selective reversible inhibitors of human monoamine oxidase-B. Int. J. Biol. Macromol. 151, 441\u2013448. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.02.144 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"53367_CR34","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1016\/j.bmcl.2016.08.044","volume":"26","author":"HW Lee","year":"2016","unstructured":"Lee, H. W. et al. Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophoraflavescens. Bioorg. Med. Chem. Lett. 26, 4714\u20134719. https:\/\/doi.org\/10.1016\/j.bmcl.2016.08.044 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"53367_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","volume":"38","author":"L Di","year":"2003","unstructured":"Di, L., Kerns, E. H., Fan, K., McConnell, O. J. & Carter, G. T. High throughput artificial membrane permeability assay for blood\u2013brain barrier. Eur. J. Med. Chem. 38, 223\u2013232. https:\/\/doi.org\/10.1016\/S0223-5234(03)00012-6 (2003).","journal-title":"Eur. J. Med. Chem."},{"key":"53367_CR36","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41598-024-51728-x","volume":"14","author":"S Kumar","year":"2024","unstructured":"Kumar, S. et al. Isatin-tethered halogen-containing acylhydrazone derivatives as monoamine oxidase inhibitor with neuroprotective effect. Sci. Rep. 14, 1264. https:\/\/doi.org\/10.1038\/s41598-024-51728-x (2024).","journal-title":"Sci. Rep."},{"key":"53367_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13765-024-00929-z","volume":"67","author":"HA Hasan","year":"2024","unstructured":"Hasan, H. A. et al. Effect of halogens on 3-[4-(dimethylamino) phenyl]-1-phenylprop-2-en-1-ones: development of a new class of monoamine oxidase-B inhibitors. Appl. Biol. Chem. 67, 73. https:\/\/doi.org\/10.1186\/s13765-024-00929-z (2024).","journal-title":"Appl. Biol. Chem."},{"key":"53367_CR38","doi-asserted-by":"publisher","first-page":"18670","DOI":"10.1021\/acsanm.3c03454","volume":"6","author":"STK Kamalasanan","year":"2023","unstructured":"Kamalasanan, S. T. K., Keechilat, S. S. P. & Harb, H. Advancing cancer treatment through nanotechnology driven immunotherapy for pancreatic cancer. ACS Appl. Nano Mater. 6, 18670\u201318697. https:\/\/doi.org\/10.1021\/acsanm.3c03454 (2023).","journal-title":"ACS Appl. Nano Mater."},{"key":"53367_CR39","unstructured":"Schr\u00f6dinger,2024-1:QikProp - A module for ADME\/Tox predictions. Available at: www.schrodinger, (2024)."},{"key":"53367_CR40","unstructured":"Schr\u00f6dinger Release 2024-4:QikProp, Schr\u00f6dinger (LLC, 2024)."},{"key":"53367_CR41","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1021\/jm070677y","volume":"50","author":"C Binda","year":"2007","unstructured":"Binda, C. et al. Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs. J. Med. Chem. 50, 5848\u20135852. https:\/\/doi.org\/10.1021\/jm070677y (2007).","journal-title":"J. Med. Chem."},{"key":"53367_CR42","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.1073\/pnas.0710626105","volume":"105","author":"SY Son","year":"2008","unstructured":"Son, S. Y. et al. Structure of human monoamine oxidase A at 2.2-\u00c5 resolution: The control of opening the entry for substrates\/inhibitors. Proc. Natl. Acad. Sci. 105, 5739\u20135744. https:\/\/doi.org\/10.1073\/pnas.0710626105 (2008).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"53367_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1039\/d4md00608a","volume":"16","author":"S Kumar","year":"2024","unstructured":"Kumar, S. et al. Inhibition of monoamine oxidases by heterocyclic derived conjugated dienones: synthesis and in vitro and in silico investigations. RSC Med. Chem. 16 (1), 221\u2013231. https:\/\/doi.org\/10.1039\/d4md00608a (2024). Epub ahead of print. PMID: 39430951; PMCID: PMC11487422.","journal-title":"RSC Med. Chem."},{"issue":"7","key":"53367_CR44","doi-asserted-by":"publisher","first-page":"6908","DOI":"10.1021\/acsomega.2c07694","volume":"8","author":"S Kumar","year":"2023","unstructured":"Kumar, S. et al. Development of Isopropyl-Tailed Chalcones as a New Class of Selective MAO-B Inhibitors for the Treatment of Parkinson\u2019s Disorder. ACS Omega. 8 (7), 6908\u20136917. https:\/\/doi.org\/10.1021\/acsomega.2c07694 (2023). PMID: 36844523; PMCID: PMC9947953.","journal-title":"ACS Omega"},{"key":"53367_CR45","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00044-024-03196-1","volume":"33","author":"X Li","year":"2024","unstructured":"Li, X. et al. Development of novel chalcone derivatives as multifunctional agents for the treatment of Alzheimer\u2019s disease. Med. Chem. Res. 33, 548\u2013561. https:\/\/doi.org\/10.1007\/s00044-024-03196-1 (2024).","journal-title":"Med. Chem. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53367-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:30:07Z","timestamp":1789039807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53367-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53367"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53367-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28345"}}